STAR-TOR- REGISTRY FOR THE EVALUATION OF THE SAFETY, TOLERABILITY AND EFFICACY OF TEMSIROLIMUS (TORISEL), SUNITINIB (SUTENT) AND AXITINIB (INLYTA) FOR THE TREATMENT OF SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA (MRCC), MANTLE CELL LYMPHOMA (MCL) AND GASTRO-INTESTINAL STROMA TUMOR (GIST).


Condition: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT00700258

Sponsor: Pfizer

Phase:

Eligibility:

  • Age: minimum 18 Years maximum 99 Years
  • Gender: All

Inclusion Criteria:

  • Patients with proven tumor of RCC, MCL or GIST by histology.
  • Informed consent signed by patient.

Exclusion Criteria:

  • Pregnancy

View trial on ClinicalTrials.gov


email news signup